No Data
No Data
BMO Capital Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $115
BioMarin Pharmaceutical: Strong Financial Outlook and Strategic Positioning Justify Buy Rating
Express News | Monopar Announces Agreement With Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate
Earnings Preview: BMRN to Report Financial Results Post-market on October 29
Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $122
Here's Why BioMarin Pharmaceutical (BMRN) Is a Strong Growth Stock
No Data
No Data